Your browser doesn't support javascript.
A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals.
Wu, Peng; Yang, Qin; Zhao, Xiaoli; Liu, Qingqing; Xi, Jing; Zhang, Fan; He, Jinke; Yang, Hang; Zhang, Chao; Ma, Zhongchen; Deng, Xiaoyu; Wang, Yong; Chen, Chuangfu.
  • Wu P; College of Life Sciences, Shihezi University, Shihezi, China.
  • Yang Q; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Zhao X; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Liu Q; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Xi J; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Zhang F; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • He J; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Yang H; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Zhang C; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Ma Z; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Deng X; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Wang Y; College of Animal Science and Technology, Shihezi University, Shihezi, China.
  • Chen C; College of Animal Science and Technology, Shihezi University, Shihezi, China; Key Laboratory of Prevention and Control of Animal Disease of Xinjiang Crops, Shihezi, China. Electronic address: chuangfu_chen@163.com.
Res Vet Sci ; 145: 46-49, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1671110
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by an infectious virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), poses a threat to the world. The suitable treatments must be identified for this disease in animals. Nanobody have therapeutic potential in the COVID-19. In this study, SARS-CoV-2 Spike RBD protein was used to make the nanobody. Nanobodies binding to the SARS-CoV-2 Spike RBD protein was obtained. Interestingly, the nanobody could bind to SARS-CoV-2 Spike S protein and RBD protein at the same time. Nanobodies were validated with a neutralizing antibody detection kit. The use of pseudoviruses confirmed that nanobodies could prevent pseudoviruses from infecting cells. We believe the nanobody are very valuable and could be used in the treatment of COVID-19. SARS-CoV-2 nanobodies can be rapidly mass-produced from microorganisms to block SARS-CoV-2 infection in vitro and in vivo with preventive and therapeutic effects.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Animals Language: English Journal: Res Vet Sci Year: 2022 Document Type: Article Affiliation country: J.rvsc.2022.02.003

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Animals Language: English Journal: Res Vet Sci Year: 2022 Document Type: Article Affiliation country: J.rvsc.2022.02.003